Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Berger, T.
Real life use of natalizumab, fingolimod, dimethylfumarate, teriflunomide and alemtuzumab in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry
MULT SCLER J. 2016; 22: 788-789.
Web of Science